Hepatic lipid droplet content regulation

Regulation of hepatic lipid droplet content is a multifactorial biological process, not a single protein or receptor target. In hepatocytes, lipid droplets (LDs) are dynamic organelles responsible for the storage and regulated release of neutral lipids, including triacylglycerol and sterol esters[1][3][4]. The balance of LD formation and turnover is controlled by complex interplay between lipogenic enzymes (such as DGATs, GPATs), lipolytic enzymes (such as ATGL/PNPLA2, LAL), autophagy pathways (lipophagy), structural proteins (seipin, perilipins), and regulatory transcription factors (PPARγ, THRs)[1][2][3][4][5][6]. Dysregulation of this process underlies hepatic steatosis, a hallmark of NAFLD/NASH and metabolic syndrome[4][6]. Pharmacological agents like pioglitazone that enhance autophagic clearance of LDs show promise for reducing hepatic steatosis[6]. However, targeting the overall process is challenging due to the many interdependent pathways and safety concerns associated with disrupting hepatic energy homeostasis. "Hepatic lipid droplet content regulation" refers to a crucial biological process involving numerous interacting proteins and pathways that maintain the balance of lipid storage and release in the liver, making it a key player in metabolic liver health but not a canonical molecular drug target[1][2][3][4][5][6][7].

Other names

Hepatic lipid droplet regulationRegulation of hepatic lipid droplet contentRegulation of hepatocyte lipid storageLipid droplet biogenesis and turnover in liver

Promotion of lipophagy (enhanced autophagic degradation of hepatic lipid droplets, as with pioglitazone through PPARγ activation)[6] - Inhibition or stimulation of lipolysis (regulation via ATGL, HSL, and related lipases) - Modulation of lipid biosynthetic enzymes (e.g., DGAT1/2, GPATs)[4] - Regulation of related signaling/transcriptional pathways (e.g., thyroid hormone signaling, PPARs)[6]